Skip to main content

Table 2 Comparison of the pro-inflammatory cytokine profile before and after 12 weeks treatment with metformin or rimonabant

From: Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss

Parameter Metformin group (n = 10) Rimonabant group (n = 10)
Baseline 12 weeks P-value Baseline 12 weeks P-value
IL-1β 86 ± 56 105 ± 89 0.17 85 ± 77 91 ± 91 0.32
IL-6 12 ± 6 13 ± 7 0.31 17 ± 8 18 ± 9 0.31
IL-7 249 ± 18 252 ± 31 0.69 235 ± 47 263 ± 49 0.11
IL-10 23 ± 32 27 ± 30 0.29 10 ± 6 10 ± 6 0.92
IL-12 203 ± 60 223 ± 83 0.11 201 ± 41 207 ± 33 0.50
TNF-α 7 ± 3 8 ± 4 0.33 9 ± 4 9 ± 4 0.99
MCP-1 294 ± 66 298 ± 88 0.80 279 ± 60 307 ± 58 0.6
INF-γ 30 ± 10 30 ± 9 0.83 30 ± 7 36 ± 9 0.6
  1. No difference in the inflammatory cytokine profile between metformin and rimonabant treated patients
  2. IL interleukin, TNF tumour necrosis factor, MCP monocyte chemotactic protein, INF interferon
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us